Brain tumors are the leading cause of cancer-related death in childhood. To combat this, the Bandopadhayay Lab uses cutting-edge genomics to: 1) Characterize driver alterations that contribute to tumor formation and 2) Develop strategies to therapeutically target these tumors. We also study the evolution of cancer cells in pediatric brain tumors during treatment to understand how tumors become resistant to treatments, and to determine how we can therapeutically overcome it.
Our goal is to find better treatments for children with brain tumors that result in improved survival rates with fewer long-term side effects.
We believe that Team Science is essential to accelerate our discoveries and are excited with with collaborators across the world.
Our current research endeavors include:
Identifying and characterizing driver genomic alterations in pediatric brain tumors. We apply next-generation sequencing approaches to identify recurrent somatic driver mutations, structural variants and non-coding alterations (including long non-coding RNAs) that drive growth of a range of pediatric brain tumors. The Bandopadhayay Lab combines genomic approaches (including single cell RNA-sequencing and DNA-sequencing approaches, spatial transcriptomics and the use of genome-scale functional modifier screens) with cancer-biology techniques to unravel the mechanisms through which these alterations contribute to tumor formation and to determine how these can be leveraged to guide diagnostic approaches and develop novel therapeutic strategies. This includes significant efforts focused on understanding how somatic driver alterations shape cell-states that drive subsequent tumor evolution and to determine how the tumor micro-environment modulates tumor progression and growth.
Characterizing chromatin complexes as therapeutic targets in pediatric brain tumors. Many pediatric brain tumors are driven by oncogenic fusion proteins or transcription factors that cannot be inhibited with small molecules. An alternate approach is to develop strategies that target the complexes with which these proteins interact. We have made significant efforts to explore the use of inhibitors that target chromatin complexes as an alternate therapeutic strategy.
Determining resistance mechanisms to current and novel therapies. Resistance to anti-cancer treatments is a major obstacle to a cure for many children. We aim to study how cancer genomes change with therapy (by comparing pre-treatment and post-treatment tumor samples) and to apply functional genomic approaches to predict how cancer cells are expected to overcome treatments. We also have an interest in developing new tools (such as the use of DNA-barcoding technology) to allow us to track the evolution of cancer cells (at single cell resolution) with treatments.
Pratiti (Mimi) BandopadhayayPediatric brain tumors are the most common ‘solid tumor’ of childhood, and some of the most challenging to treat. While the cure rates for many childhood cancers have improved, brain tumors remain the leading cause of cancer-related death in children, with some tumors completely lacking curative treatments. However, with the recent explosion of technologies for profiling cancer genomes, our knowledge of childhood cancers is growing by leaps and bounds, such that we are, for the first time, starting to understand how childhood brain tumors grow. In her talk, Mimi will discuss the challenges in treating children with brain tumors, and will highlight how the path to precision medicine is providing tremendous hope that improved treatments will come about for children diagnosed with brain tumors.About Midsummer Nights' ScienceMidsummer Nights' Science is an annual lecture series that explores key advances in genomics and medicine, and fosters conversation between Broad scientists and the local community about the intersection of science and society. This lecture series — which is geared for those with little to no formal scientific education or background — is held each summer, and is free and open to the general public.
Posted by Broad Institute of MIT and Harvard on Wednesday, July 25, 2018